Carvedilol is superior to metoprolol for prevention of vascular effects in heart failure
This article has no abstract so we have provided the first paragraph of the full text.
Carvedilol has the capacity to block both the 
-1 and -2 adrenergic receptors, as well as the 
-1 receptors. There is evidence to indicate that full adrenergic blockade by carvedilol improves survival and cardiovascular outcome in patients with heart failure compared with metoprolol treatment, which blocks the -1 receptors only.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
L-DOPA, dyskinesia and striatal plasticityNature Neuroscience News and Views (01 May 2003)
